| Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer RZ Szmulewitz, CJ Peer, A Ibraheem, E Martinez, MF Kozloff, B Carthon, ... Journal of Clinical Oncology 36 (14), 1389, 2018 | 170 | 2018 |
| Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results DJ Press, A Ibraheem, ME Dolan, KH Goss, S Conzen, D Huo Breast cancer research and treatment 168, 207-220, 2018 | 32 | 2018 |
| Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base A Ibraheem, OI Olopade, D Huo Cancer 126 (17), 4013-4022, 2020 | 30 | 2020 |
| Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: who benefits from chemotherapy? AF Ibraheem, DJ Press, OI Olopade, D Huo Cancer 125 (2), 213-222, 2019 | 30 | 2019 |
| Racial disparities in survival outcomes among breast cancer patients by molecular subtypes F Zhao, B Copley, Q Niu, F Liu, JA Johnson, T Sutton, G Khramtsova, ... Breast cancer research and treatment 185, 841-849, 2021 | 29 | 2021 |
| Infrastructural challenges lead to delay of curative radiotherapy in Nigeria J Leng, AI Ntekim, A Ibraheem, CP Anakwenze, DW Golden, OI Olopade JCO global oncology 6, 269-276, 2020 | 26 | 2020 |
| Improving the accrual of racial and ethnic minority patients in clinical trials: time to raise the stakes A Ibraheem, B Polite Cancer 123 (24), 4752-4756, 2017 | 22 | 2017 |
| Implementing oncology clinical trials in Nigeria: a model for capacity building A Ntekim, A Ibraheem, A Adeniyi-Sofoluwe, T Adepoju, M Oluwasanu, ... BMC Health Services Research 20, 1-9, 2020 | 16 | 2020 |
| Cancer clinical trials in Africa—An untapped opportunity: Recommendations from AORTIC 2019 conference special interest group in clinical trials A Ibraheem, C Pillai, I Okoye, JJ Smith, D Reidy-Lagunes, G Macaulay, ... JCO Global Oncology 7, 1358-1363, 2021 | 13 | 2021 |
| Association of social determinants and tumor biology with racial disparity in survival from early-stage, hormone-dependent breast cancer KF Hoskins, GS Calip, HC Huang, A Ibraheem, OC Danciu, GH Rauscher JAMA oncology 9 (4), 536-545, 2023 | 12 | 2023 |
| Referral patterns and clinical outcomes for transplant-eligible lymphoma and myeloma patients evaluated at an urban county hospital HD Yun, T Dossul, L Bernal-Mizrachi, J Switchenko, C Ndibe, A Ibraheem, ... Journal of stem cell research & therapy 6, 2016 | 10 | 2016 |
| Formal assessment of teamwork among cancer health care professionals in three large tertiary centers in Nigeria AF Ibraheem, M Giurcanu, AC Sowunmi, O Awolude, M Habeebu, ... JCO Global Oncology 6, 560-568, 2020 | 7 | 2020 |
| A prospective international randomized phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with … RZ Szmulewitz, AF Ibraheem, CJ Peer, WD Figg, BC Carthon, M Kozloff, ... Journal of Clinical Oncology 35 (6_suppl), 176-176, 2017 | 6 | 2017 |
| Chemotherapy-induced cardiotoxicity in breast cancer patients A Ibraheem, TJ Stankowski-Drengler, OB Gbolahan, JM Engel, AA Onitilo Breast Cancer Management 5 (1), 31-41, 2016 | 6 | 2016 |
| ARETTA: Assessing response to neoadjuvant taxotere and subcutaneous trastuzumab in Nigerian women with HER2-positive breast cancer: A study protocol AI Ntekim, A Ibraheem, AA Sofoluwe, O Kotila, C Babalola, T Karrison, ... JCO global oncology 6, 983-990, 2020 | 5 | 2020 |
| Community clinical practice patterns and mortality in patients with Oncotype DX intermediate score: who benefits from chemotherapy? AF Ibraheem, DJ Press, OI Olopade, D Huo Cancer 125 (2), 213, 2019 | 3 | 2019 |
| Survey of medical student knowledge in oncology and survivorship care in Nigeria: A pilot study. J Leng, AF Ibraheem, AI Ntekim, A Popoola, L Agaga, E Ukoh, ... Journal of Clinical Oncology 37 (15_suppl), e18106-e18106, 2019 | 2 | 2019 |
| SIRFLOX: progression-free survival in the liver as a surrogate end point for survival? AO Ayoola, AF Ibraheem J Clin Oncol 34 (34), 4193, 2016 | 2 | 2016 |
| Consensus molecular subtyping of colorectal cancer by immunohistochemistry, an imperative for a resource limited setting: Report of a Nigerian study FB Abdulkareem, G Khramtsova, LA Odukoya, KB Badmos, T Adedokun, ... Nigerian Journal of Gastroenterology and Hepatology 13 (2), 33-39, 2021 | 1 | 2021 |
| Abstract SS1-06: Racial disparities in pathological complete response among breast cancer patients receiving neoadjuvant chemotherapy F Zhao, M Steiner, A Ibraheem, G Fleming, N Jaskowiak, R Nanda, ... Cancer Research 81 (4_Supplement), SS1-06-SS1-06, 2021 | 1 | 2021 |
